Overview

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The study is being performed in order to learn more about the safety and tolerability of AZD1386. AZD1386 is primary intended for treatment of chronic pain.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca